Arbor Biotechnologies Strengthens Leadership With The Appointment Of Don Haut, Ph.D., As Chief Business Officer

Arbor Biotechnologies, Inc., a biotechnology company focused on developing the next generation of genetic medicines, has announced the appointment of Don Haut, Ph.D., as Chief Business Officer. In this role, Dr. Haut will lead corporate strategy and business development efforts as Arbor advances its proprietary portfolio of gene editing therapies targeting liver and central nervous system diseases. Dr. Haut brings over 20 years of experience in the life sciences industry, specializing in business development and contributing to the progress of numerous drugs and medical devices. 

Prior to joining Arbor, he was Chief Business Officer at EG-427, a French biotech company working on gene therapies for chronic conditions. He also served as Chief Executive Officer of Carmine Therapeutics and Chief Business Officer at Asklepios Biosciences (AskBio), where he played a key role in the company’s acquisition by Bayer. Earlier in his career, Dr. Haut held leadership positions at Sherlock Biosciences, Histogenics, the Medicines Company, and Lane-4 Advisors, providing strategic and financial guidance to various life sciences firms. 

Devyn Smith, Ph.D., Chief Executive Officer of Arbor Biotechnologies, stated, “Don joins us at an exciting time as we advance our lead program, ABO-101, into the clinic and progress our broader pipeline of gene editing therapeutics. His extensive expertise in executing transactions and building strategic partnerships across diverse modalities and therapeutic areas will be invaluable as we leverage our differentiated gene editing capabilities to fuel a new generation of potentially curative genetic medicines.”

Dr. Haut, Chief Business Officer of Arbor, said in a statement, “Arbor’s unique suite of gene editors and strong pipeline of differentiated therapeutics addressing liver and CNS diseases position the company to make a significant impact on the lives of individuals with serious genetic diseases. I look forward to working with this talented team to progress the company’s mission of delivering transformative gene editing therapeutics to the patients who need them most.”

He has been involved in global transactions totaling more than $8.5 billion across different therapeutic areas and stages of development. Currently, he serves as Board Chairman of IMMvention Therapeutics and as an independent Director at Aspect Biosystems and Orthox, Ltd. Dr. Haut earned his Ph.D. in Molecular Microbiology and Immunology from the University of Missouri and holds an MBA from Washington University’s Olin School of Business.